Mucus secretions from the female reproductive tract are extremely difficult to penetrate even by virus-sized objects. Why then do these barriers sometimes fail to protect against sexually transmitted pathogens? Our pilot data suggests some pathogens are too large to penetrate mucus mesh-spacing (pore size), and mucus also traps some pathogens like fly-paper before they can reach target cells. In contrast, abnormal mucus may not be so protective. About 1 in 3 women have bacterial vaginosis (BV), and they are at >2-6-fold increased risk of infection by HIV and other viral, bacterial, and protozoan pathogens. BV is a polymicrobial overgrowth of vaginal flora that decimates healthy lactobacilli, transforms vaginal mucus to a watery secretion, and partially eliminates the acidity of the vagina. We have developed mucus penetrating particles (MPP) that reveal the mucus mesh-spacing in fresh human samples. We can thus identify pathogens that are slowed in ex vivo genital mucus fluids by steric occlusion (pathogen size >mesh-spacing) and/or trapped by adhesion. Our pilot observations indicate native (acidic) cervicovaginal mucus from women with healthy vaginal flora adhesively traps HPV, HIV, and HSV. But, if partially neutralized with NaOH to mimic neutralizing actions of BV, HIV and HSV can penetrate this mucus barrier. Our overall hypothesis is that mucus secretions from women with healthy vaginal flora are highly protective against pathogen penetration, but that this protection is greatly diminished in women with BV. To test this, Aim 1 will extend our pilot observations and include all mucus secretions through which STD pathogens are usually transmitted: endocervical mucus, healthy cervicovaginal mucus, BV secretions, and semen. We will use multiple particle tracking and MPP to characterize the meshspacing and protective viscoelastic properties of these genital secretions at the nano- to micro- length scales experienced by pathogens.
Aim 2 will identify the secretions that can block or retard penetration by major STD pathogens (HIV, HSV, HPV, N. gonorrhoeae and C. trachomatis), and secretions that are rapidly penetrated. We will also determine the exact viscosity and elasticity experienced by each pathogen in the various human secretions. This will provide important quantitation of the extent of impediment each pathogen experiences. Taken together, the results from Aims 1 &2 will also distinguish pathogens blocked sterically, and those trapped adhesively, in each secretion.
Aim 3 will investigate the roles of lactic acid, and lactate anions, in causing STD pathogens to be trapped by mucus. Our pilot results show lactic acid specifically alters the surfaces of HIV and HSV, and this may help explain how they are trapped by healthy mucus. This project will likely clarify how abnormal mucus secretions caused by BV increase susceptibility to penetration of a broad range of viral, bacterial, and protozoal pathogens. The results may also support the creation of new methods that use lactic acid to help prevent BV and enhance the protective effects of mucus secretions
Women with healthy vaginal flora (lactobacilli) are at markedly less risk of HIV, HSV, HPV, and several STD bacteria and protozoa than women with bacterial vaginosis (BV). Unfortunately, only a minority of women (<40%) have healthy vaginal flora and at any given time about 1 in 3 women have BV. This project will help reveal how healthy vaginal flora helps protect against infection and how BV increases susceptibility to infections;the results will likely support developing vaginal products and microbicides that reinforce the broad- spectrum protective actions of vaginal lactic acid.
|Xu, Qingguo; Ensign, Laura M; Boylan, Nicholas J et al. (2015) Impact of Surface Polyethylene Glycol (PEG) Density on Biodegradable Nanoparticle Transport in Mucus ex Vivo and Distribution in Vivo. ACS Nano 9:9217-27|
|Schuster, Benjamin S; Ensign, Laura M; Allan, Daniel B et al. (2015) Particle tracking in drug and gene delivery research: State-of-the-art applications and methods. Adv Drug Deliv Rev 91:70-91|
|Ensign, Laura M; Cone, Richard; Hanes, Justin (2014) Nanoparticle-based drug delivery to the vagina: a review. J Control Release 190:500-14|
|Ensign, Laura M; Lai, Samuel K; Wang, Ying-Ying et al. (2014) Pretreatment of human cervicovaginal mucus with pluronic F127 enhances nanoparticle penetration without compromising mucus barrier properties to herpes simplex virus. Biomacromolecules 15:4403-9|
|Yang, Ming; Yu, Tao; Wang, Ying-Ying et al. (2014) Vaginal delivery of paclitaxel via nanoparticles with non-mucoadhesive surfaces suppresses cervical tumor growth. Adv Healthc Mater 3:1044-52|
|Wang, Ying-Ying; Lai, Samuel K; Ensign, Laura M et al. (2013) The microstructure and bulk rheology of human cervicovaginal mucus are remarkably resistant to changes in pH. Biomacromolecules 14:4429-35|
|Ensign, Laura M; Hoen, Timothy E; Maisel, Katharina et al. (2013) Enhanced vaginal drug delivery through the use of hypotonic formulations that induce fluid uptake. Biomaterials 34:6922-9|
|Ensign, Laura M; Henning, Andreas; Schneider, Craig S et al. (2013) Ex vivo characterization of particle transport in mucus secretions coating freshly excised mucosal tissues. Mol Pharm 10:2176-82|
|Ensign, Laura M; Cone, Richard; Hanes, Justin (2012) Oral drug delivery with polymeric nanoparticles: the gastrointestinal mucus barriers. Adv Drug Deliv Rev 64:557-70|
|Wang, Ying-Ying; Lai, Samuel K; So, Conan et al. (2011) Mucoadhesive nanoparticles may disrupt the protective human mucus barrier by altering its microstructure. PLoS One 6:e21547|